| 词条 | Amibegron |
| 释义 |
| Watchedfields = changed | verifiedrevid = 437193151 | IUPAC_name = Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate | image = Amibegron.svg | width = 250 | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = Development terminated | routes_of_administration = Oral | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 121524-09-2 | ATC_prefix = none | ATC_suffix = | PubChem = 3035442 | IUPHAR_ligand = 568 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 108738 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = PDQ3ME68U3 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D08851 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 545437 | C=22 | H=26 | Cl=1 | N=1 | O=4 | molecular_weight = 403.898 g/mol | smiles = CCOC(=O)COc3ccc1CCC(Cc1c3)NCC(O)c2cc(Cl)ccc2 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C22H26ClNO4.ClH/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16;/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3;1H/t19-,21-;/m0./s1 | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = NQIZCDQCNYCVAS-RQBPZYBGSA-N }}Amibegron (SR-58,611A) was a drug developed by Sanofi-Aventis (now Sanofi) which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the central nervous system, and has antidepressant and anxiolytic effects.[1][2] On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.[3] References1. ^Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. {{PMID|17460614}} {{Antidepressants}}{{Anxiolytics}}{{Adrenergics}}{{nervous-system-drug-stub}}2. ^Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology Biochemistry and Behavior. 2008 Jun;89(4):623-6. {{DOI|10.1016/j.pbb.2008.02.020}} {{PMID|18358519}} 3. ^Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009. 6 : Abandoned drugs|Alcohols|Beta3-adrenergic agonists|Chloroarenes|Phenol ethers|Tetralins |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。